Firestone Institute for Respiratory Health
Hamilton, Ontario, L8N 4A6, Canada
NCT Number: NCT00989521
PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma.
Study objectives are to :
1. to evaluate the safety of PUR003 in subjects with asthma, and 2. to evaluate the efficacy of PUR003 in assisting the treatment of asthma.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Hamilton, Ontario, L8N 4A6, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PUR003 for inhalation
Normal saline for inhalation
Time frame: after three doses
Pulmatrix Inc.
Industry
Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03688074
Asthma, Bronchial Diseases
Denver, Colorado, United States
View Trial DetailsNCT02162576
Asthma, Bronchial Diseases
Louisville, Kentucky, United States
View Trial DetailsNCT06272370
Asthma, Bronchial Diseases
Aurora, Colorado, United States
View Trial DetailsNCT04170348
Acute Chest Syndrome, Anemia
New York, United States
View Trial Details